<code id='1F57D72543'></code><style id='1F57D72543'></style>
    • <acronym id='1F57D72543'></acronym>
      <center id='1F57D72543'><center id='1F57D72543'><tfoot id='1F57D72543'></tfoot></center><abbr id='1F57D72543'><dir id='1F57D72543'><tfoot id='1F57D72543'></tfoot><noframes id='1F57D72543'>

    • <optgroup id='1F57D72543'><strike id='1F57D72543'><sup id='1F57D72543'></sup></strike><code id='1F57D72543'></code></optgroup>
        1. <b id='1F57D72543'><label id='1F57D72543'><select id='1F57D72543'><dt id='1F57D72543'><span id='1F57D72543'></span></dt></select></label></b><u id='1F57D72543'></u>
          <i id='1F57D72543'><strike id='1F57D72543'><tt id='1F57D72543'><pre id='1F57D72543'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:hotspot    - browse:8
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot